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Objectives This study sought to evaluate the exact location of Edwards SAPIEN (Edwards Lifesciences,
Irvine, California) devices in different stages of implantation and to quantify possible operator-independent
device movement during ﬁnal deployment.
Background Accurate device positioning during transcatheter aortic valve implantation is crucial in
order to achieve optimal results.
Methods This multicenter study consisted of 68 procedures with reliable pacemaker capture. Device posi-
ions were assessed using ﬂuoroscopic images and the C-THV system (Paieon Medical, Rosh Ha’Ayin, Israel).
esults The location after implantation was signiﬁcantly higher than in the ﬁnal stage of rapid pacing:
6.7  16.3% of device height below the plane of the lower sinus border versus 32.6  13.8%, p 
0.0001. Operator-independent device-center upper movement during ﬁnal deployment was 2  1.43 mm,
range: 1.3 to 4.6 mm. Device movement was asymmetrical, occurring more in the lower part of the
device than in its upper part (3.2  1.4 mm vs. 0.75  1.5 mm, p  0.001), resulting in device shorten-
ing. Multivariate analysis revealed that moderate and severe aortic valve calciﬁcation had 49% higher
upward movement than mild calciﬁcation (p  0.03), and aortic sinus volume was negatively correlated
with movement size (r  0.35, p  0.005). This movement was independent of device version (SAPIEN
vs. SAPIEN XT), procedural access (transfemoral vs. transapical), and interventricular septum width.
Conclusions The ﬁnal Edwards SAPIEN position is mostly aortic in relation to the lower sinus bor-
der. There is an operator-independent upward movement of the device center during the ﬁnal
stage of implantation. Anticipated upward movement of the device should inﬂuence its positioning
before ﬁnal deployment. (J Am Coll Cardiol Intv 2012;5:563–70) © 2012 by the American College of
Cardiology Foundation
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564Transcatheter aortic valve replacement (TAVR) is an alter-
native treatment for severe symptomatic aortic valve stenosis
in high-risk patients (1,2). To achieve optimal results and
avoid complications, implanted valves must be precisely
positioned (3,4). Significantly low implantation can cause
severe paravalvular regurgitation, residual stenosis, mitral
insufficiency, conduction abnormality, and in extreme cases,
device drop into the left ventricular cavity, whereas consid-
erably high implantation could result in paravalvular regur-
gitation, coronary flow obstruction, and device embolization
(5–8). These complications could lead to patient instability
and occasionally require further interventions, such as im-
plantation of another device or an emergent surgery (9,10).
Therefore, meticulous implantation technique is required to
ensure precise positioning.
During implantation of an Edwards SAPIEN device
(Edwards Lifesciences, Irvine, California), rapid pacing is
performed to stabilize the device throughout balloon infla-
tion and to prevent its ejection toward the aorta. This crucial
stage is universally associated with temporary hemodynamic
instability; hence, device positioning needs to be performed
as quickly and safely as possible. However, conventional
imaging modalities, mainly fluoroscopy, aortography, and
echocardiography, have limited ability to guide the operator
in accurate positioning of the
prosthetic device in relation to
the native valve (11). This be-
comes even more difficult in the
presence of an extremely irregular
anatomy, such as in highly tortuous
aorta; in these cases, TAVR using non-repositionable devices
carries a significant risk. Moreover, even in cases with optimal
pacing performance, there may be some operator-
independent movement of the device toward the aorta
during final device deployment (4). This upward movement
has not yet been quantified in a cohort of TAVR proce-
dures, and the optimal position of the Edwards SAPIEN
device before final deployment is as yet unknown.
The objectives of the present study were to analyze
Edwards SAPIEN devices positions in different stages of
implantation and to quantify possible device movement
during final deployment.
Methods
A cohort of 109 patients with severe symptomatic native
aortic valve stenosis treated with Edwards SAPIEN TAVR
procedures at 4 major medical centers from January 2010 to
December 2010 were screened prospectively for this study
(Charles Nicolle Hospital, Rouen, France; Hôpital Bichat,
Paris, France; Rabin Medical Center, Petach Tikva, Israel;
Shaare Zedek Medical Center, Jerusalem, Israel). Institu-
tional committee on human research approved the study
Abbreviation and
Acronym
TAVR  transcatheter aortic
valve replacementprotocol. To prevent technical inaccuracies and to allow the ause of quantitative processing techniques with improved
reproducibility, only cases that met the following criteria
were included: similar angiographic views during device
positioning and implantation (15° separation in all
planes); aortographic contrast injection usage before and
after device deployment; and appearance of a visible calcium
spot during all measurement stages. In addition, reliable
capture of the pacemaker at a rate of at least 180 beats/min,
with loss of pulsatile flow was mandatory. Cases with
operator-induced device movement during the rapid pacing
stage were excluded.
Clinical and echocardiographic data were collected. An-
atomic measurements of the ascending aorta and aortic root
were collected using fluoroscopic images obtained before
device implantation: sinus width, sinus height (between the
level of the lower sinus border plane and the sinotubular
junction plane), diameter of the sinotubular junction and
the ascending aorta. Degree of aortic valve calcification was
defined according to fluoroscopic images: no, no calcifica-
tion visible; mild, calcification visible but does not include
the entire valve plane; moderate, calcification includes the
entire valve plane without the sinuses; and severe, calcifica-
tion includes the entire valve plane and the sinuses. Esti-
mation of sinus volume (cm3) was calculated as: sinus height
(mm)  (annulus diameter [mm]/2)2/1,000. Degree of
aortic regurgitation was defined according to aortographic
measurements in a scale of 1 to 4: mild regurgitation
(1) when only a small amount of contrast enters the left
ventricle and does not fill the chamber; moderate regurgi-
tation (2) when the contrast faintly fills the entire ventricle
and does not clear rapidly; moderate-severe (3) when
ventricle opacification is equal in density to the ascending
aorta; and severe (4) when it is greater than in the aorta.
Deﬁnition of device position. The virtual ring formed by
oining the points of basal attachment of the aortic valve
eaflets, representing the plane of the virtual aortic valve
nnulus, anatomic annulus (Fig. 1A), served as a reference
or the location of the device. Device position was defined as
he fraction below the anatomic annulus, in relation to the
otal prosthetic valve height (Figs. 1B–1D). After device
mplantation, when the virtual valve annulus is no longer at
ts original position, we used a fixed anatomic structure as
he reconstructed line reference, namely, the sinotubular
unction and the sinus curve complex constructs.
Measurements of device position. Position measurements
ere performed using the C-THV (Paieon Medical, Rosh
a’Ayin, Israel) system to identify the device position
ffline. The C-THV is an imaging modality that creates a
-dimensional reconstruction of the aortic root during
dwards SAPIEN TAVR procedures, and enables real-
ime device positioning in relation to a pre-defined target
ine (12–14). To accurately evaluate the position of the
mplanted device, 4 components of the native valve and the
ortic root complex were marked during the planning stage:
t
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565the anatomic annulus at the base of the sinuses, the sinotubular
junction, the aortic root complex, and a calcium spot. In each
case, these components were verified by an independent
observer blinded to initial selections. The plane of the aortic
valve anatomic annulus was tracked until it was completely
filled with contrast medium. This plane was used to identify
the basal region of the sinuses. A visible calcium spot adjacent
to the aortic root was identified as well. The stable position of
this calcium spot and its fixed spatial relationship to the valve
anatomic annulus allowed us to accurately recognize the plane
of the aortic valve annulus and to evaluate device location
without the need for additional contrast injection. Semiauto-
matic segmentation of the selected calcium spot was performed
before and after device implementation.
We documented the prosthetic device positions in each
patient at 4 stages during the procedure: 1) pre-deployment,
before contrast injection (guided by the pre-selected calcium
spot); 2) pre-deployment, during the last angiographic
aortic contrast injection (guided by the aortographic image
showing the fixed sinotubular junction and target line at the
base of sinuses); 3) during rapid pacing, immediately before
balloon inflation (guided by the pre-selected calcium spot);
and 4) post-deployment, after device implantation (guided
by the pre-defined fixed sinotubular junction and recon-
structed target line). In each stage, we measured the following
parameters in relation to the target line and the sinotubular
junction: the fraction of the device below the anatomic annulus
out of the total prosthetic device length, and the position of the
upper, middle, and lower parts of the device.
Statistical analysis. Statistical analysis was performed with
he SAS version 9.1 (SAS Institute, Cary, North Carolina).
Figure 1. Edwards SAPIEN Device Positions
Edwards SAPIEN device in a closed conﬁguration in several positions, deﬁned
relation to the total prosthetic valve height. (A) The anatomical annulus plane
lus (50% position). (C) The device is positioned very low (80% position). (D) Thontinuous variables are presented as mean  SD, and dategorical variables as proportions and percentages. Differ-
nces in paired continuous variables were assessed by Stu-
ent t test. Correlations between clinical parameters and
device movement were calculated using Pearson correlation
coefficients. Significance was set at p  0.05.
Results
Sixty-eight patients (62% women) of mean age 82.9  7.2
years were included in the analysis. There were no differ-
ences in background and clinical characteristics between
patients who were included in the study and those excluded.
Their clinical and anatomic characteristics, as well as early
clinical results, are detailed in Tables 1 and 2. There were no
cases of coronary ostial obstruction, a need for a second
device implantation because of malpositioning, or an emer-
gent cardiac surgery. Two patients (2.9%) required perma-
nent pacemaker implantation after the procedure. Edwards
SAPIEN devices were implanted in 36 patients (52.9%),
and Edwards SAPIEN XT devices in 32 patients (47.1%).
Transfemoral (43 cases, 63.2%) or transapical (25 cases,
36.8%) routes were used for access.
Before deployment, the fraction of device height below
the anatomic annulus was 36.9  21.5%, guided by the
pre-selected calcium spot without aortic contrast injection,
and 39  14.7%, guided by the aortographic image with
contrast injection. There was no significant difference be-
tween these values (p  0.51).
Device position during rapid pacing, immediately before
balloon inflation, was highly correlated with its position
after deployment (r2  0.68, p  0.001) (Fig. 2). After
ice fraction below the basal sinus border (anatomic annulus, green line) in
basal sinus border. (B) The device is centralized against the anatomic annu-
ice is positioned very high (20% position).as dev
at theeployment, the position of the device (16.7 16.3% below
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566the anatomic annulus) was significantly higher than during
rapid pacing (32.6 13.8%, p 0.0001) (Figs. 3 and 4). In
91.2% of cases, final device location was40% of the device
height below the anatomic annulus. Absolute device move-
ment toward the aorta between the final rapid pacing period
and device deployment was 2  1.43-mm upward movement
of device center (range: 1.3 to 4.6 mm). This upward
ovement was asymmetrical and occurred mainly in the lower
Table 1. Patient Characteristics (N  68)
Baseline demographics
Age, yrs 82.9 7.2
Male 38.2
NYHA functional class I/II/III/IV 0%/4.4%/51.5%/44.1%
Diabetes mellitus 23.5
Hypertension 88.2
Peripheral vascular disease 33.8
Renal failure (GFR 60 ml/min) 39.7
Previous cardiac surgery 25
Logistic euroSCORE 23.2 8.5
STS score 9.1 4.2
Prosthesis size (23 mm/26 mm) 48.5%/51.5%
Device (SAPIEN/SAPIEN XT) 52.9%/47.1%
Vascular access (transfemoral/transapical) 63.2%/36.8%
30-day clinical and echocardiographic results
Survival 94.1
NYHA functional class I/II/III/IV 35.3%/47.1%/16.2%/1.5%
Left-ventricular ejection-fraction 54.8 13.5
Aortic regurgitation grade 2 17.7
Aortic-valve maximal pressure gradient, mm Hg 19.2 9.5
Aortic-valve mean pressure gradient, mm Hg 9.8 5
Values are mean SD or %.
GFRglomerular filtration rate;NYHANewYorkHeartAssociation; STSSocietyof Thoracic
Surgeons.
Table 2. Baseline Echocardiographic and Angiographic
Characteristics (N  68)
Aortic valve maximum pressure gradient, mm Hg 85.9 22.9
Aortic valve mean pressure gradient, mm Hg 53.6 18.1
Aortic valve area, cm2 0.56 0.13
Aortic regurgitation grade 2 29.4
Left ventricular ejection fraction, % 53.8 12.6
Aortic valve annulus diameter, mm 22.1 1.9
Proximal ascending aorta diameter, mm 31 3.6
Intraventricular septum diameter, mm 13.5 3.8
AV calciﬁcation (no/mild/moderate/severe) 0%/33.8%/48.5%/17.6%
Aortic root sinus width, mm 31.9 5.9
Sinus root sinus height, mm 18.7 4.2
Sinotubular junction width, mm 27.8 6.7
Ascending aorta diameter, mm 33.6 5.2
Aortic valve angulation,° 38.6 10.9
Aortic sinus volume, cm3* 7.2 2.38
Values are mean  SD or %. *Estimation of sinus volume (cm3) was calculated as: sinus height
(mm)  (annulus diameter [mm]/2)2/1,000.AV atrioventricular.part of the device (3.2 1.4 mm vs. 0.75 1.5 in upper part,
 0.001), resulting in device shortening (Fig. 5).
Table 3 shows several correlations between device-center
ovement and clinical characteristics. The upward move-
ent was independent of device type (Edwards SAPIEN vs.
dwards SAPIEN XT), size (23 vs. 26 mm), and proce-
ural access (transfemoral vs. transapical). There was also no
ignificant influence of baseline device position (high vs.
id/low position) on its movement. Significant (moderate
r severe) aortic valve calcification was associated with a
9% higher upward movement than mild calcification
2.28  1.15 mm vs. 1.53  1.61 mm, p  0.03). Aortic
inus volume was significantly negatively correlated with
hat movement (r  0.35, p  0.005), and a trend was
found between that movement and either higher baseline
aortic regurgitation severity (p  0.07) or native aortic valve
annulus (p  0.09). There was no significant correlation
etween final device position and clinical or hemodynamic
esults.
iscussion
The present multicenter analysis of a cohort of TAVR
procedures using Edwards SAPIEN devices yielded several
findings. First, the position of the device during rapid
pacing, before final implantation, was relatively higher (i.e.,
toward the aorta) than conventionally recommended (4).
Average device location during rapid pacing was 32.6% of
Figure 2. Edwards SAPIEN Device Position During Rapid Pacing
and After Implantation
Correlation between Edwards SAPIEN device positions (deﬁned as device
fraction below the basal sinus border) during rapid pacing, immediately
before implantation, and after deployment. r2  0.68, p  0.001.device height below the anatomic annulus and 67.4% above
us bo
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567that plane. Nevertheless, early clinical results were satisfac-
tory and comparable to contemporary registries of Edwards
SAPIEN procedures in terms of patient survival, functional
class, and valve hemodynamics (1,2,15,16). Second, even
Figure 3. Case Examples
Operator-independent upward Edwards SAPIEN device movement between th
deployment. Numbers represent the fraction of the device below the basal sinunder proper rapid pacing, there is a considerable (averageof 2 mm) upward, operator-independent movement of the
device center during the final stage of implantation, which
leads to an even higher location. This upward movement
was more significant in cases of small aortic sinus volume
stage of rapid pacing, immediately before balloon inﬂation, and after device
rder (anatomic annulus, red line).e ﬁnaland significant aortic valve calcification. Third, the lower
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568portion of the device accounts for most of the upward
movement (average of 3.2 mm), whereas the upper border of
the device is relatively fixed (average of 0.75 mm), leading to
device shortening (Online Video 1).
Device shortening and upper movement. Our study results
support the manufacturer specifications of 2- to 3-mm
device shortening from the crimped to open configuration
Figure 4. Edwards SAPIEN Device Positions
A graph displaying Edwards SAPIEN device locations of 68 patients in the
ﬁnal stage of rapid pacing, immediately before balloon inﬂation, and after
deployment. Numbers represent the fraction of the device below the basal
sinus border (anatomic annulus). There is a change in average device loca-
tion from 32.6  13.8% to 16.7  16.3%.
Figure 5. Illustration of Average Edwards SAPIEN Device Position and Ope
(A) The device in closed conﬁguration, during the ﬁnal stage of rapid pacing,
border (anatomic annulus, green line). (B) The device after deployment positi
ment between the ﬁnal stage of rapid pacing and deployment with 2  1.43-
1.4 mm; upper device border movement: 0.75  1.5 mm. See Online Video 1.(17). Although the exact shortening and upper movement
mechanism is not clear, decrease in device height appears to
be asymmetrical, where the upper device part is relatively
fixed by the calcified leaflets, and the released lower part is
moving upward. This differential movement might have
some clinical benefits where upper movement of the lower
device border could decrease the tension on the interven-
tricular septum, and possibly reduce the rates of conduction
defect after the procedure, whereas the relatively fixed
position of the upper device border may decrease the risk of
coronary ostia obstruction. Nevertheless, malpositioning
could still result in significant valve regurgitation, and in
extreme cases, may lead to device dislocation. According to
our study results, the fixation of the upper part might be
more pronounced in cases with significant valve calcification
and small aortic sinus volume. It is conceivable that the
impact of native valve calcification on device movement
during deployment is dictated by the exact location and
interplay between the device and calcification in a similar way
that it may affect the degree of perivalvular leak after implan-
tation (18). Nevertheless, an alternative mechanism of device
movement could include symmetrical shortening of the device,
from both upper and lower borders, followed by an upper
device shift toward the aorta. However, this alternative hy-
pothesis does not explain the relatively fixed position of the
upper border of the device that was revealed in the study.
Several clinical characteristics formerly thought to impact
device stability during implantation were not found as such in
ndependent Change During Final Implantation
iately before balloon inﬂation. It is positioned 33% below the basal sinus
16% below the anatomical annulus. (C) Operator-independent device move-
pward movement of device center. Lower device border movement: 3.2 rator-I
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AV atrioventricular; NA not applicable
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569our study (4). Specifically, a newer version of the SAPIEN
device (SAPIEN XT) and the use of a transapical route of
implantation did not decrease upper device movement. By
contrast, a high degree of septal hypertrophy (i.e., bulging
interventricular septum) was not associated with device insta-
bility. Nevertheless, the degree of pre-procedural aortic regur-
gitation tended to correlate with the degree of device
movement.
Optimal deployment position. Even when a perpendicular
iew of the device is achieved, using the optimal projection
ethod of the C-THV system, the optimal deployment
ocation of the Edwards SAPIEN device is controversial. Most
avorable results will probably be gained when full coverage of
he aortic leaflets is obtained with secure anchoring at and
elow the level of the insertion of the native valve leaflets.
herefore, the conventional recommendation is to implant the
evice and 50% below and 50% above native leaflet insertion.
owever, the precise location of leaflet insertion is not easy to
efine using conventional real-time catheterization laboratory
maging, and an approximation of the aortic annulus location is
sually made. However, the aortic annulus is not an anatomic
tructure, and the virtual basal ring, which commonly serves as
he target line for implantation, forms at the plane of the base
f the aortic sinuses, about 1 to 2 mm below the anatomic
entriculoaortic junction (leaflet hinge points) (3). Moreover,
he skirt of the Edwards SAPIEN device surrounds mostly the
ower part of the implanted device struts and not the upper
art. Therefore, it seems reasonable to suggest that the final
ocation of the middle region of implanted device will be 1 to
mm higher than the plane of the most basal part of the aortic
inuses. Our findings of slightly higher device implantations
han the basal sinus border with satisfactory clinical results are
ompatible with this suggestion. Aiming for a slightly high
alve position will decrease the risk of low malposition, a
omplication that may result in a severe complication of device
rop into the left ventricular cavity with a subsequent need for
mergent surgery. Slightly high valve position may also dimin-
sh the risk of conduction system abnormalities, although the
orrelation between implantation depth and a need for perma-
ent pacemaker implantation after the procedure was studied
ostly in patients undergoing CoreValve device (Medtronic,
inneapolis, Minnesota) implantation (19,20). Nevertheless,
n patients with low left main ostia that are considered for
ranscatheter valve implantation (especially those8 mm from
he virtual basal ring), in addition to considering the use of a
afety guidewire in the coronary artery, the operator should aim
or a lower implantation to decrease the risk of ostial coronary
cclusion.
Clinical implications. It seems that operators implanting
Edwards SAPIEN devices need to be aware of the upper
movement phenomenon. This operator-independent
change in device position was as common in the new
SAPIEN device version as in the previous version. InTable 3. Device Movement During Final Deployment According to
Clinical and Anatomic Parameters*
Parameter
Upward Device
Movement
(mm)
Pearson
Correlation
Coefficient p Value
Baseline characteristics
Aortic valve maximum pressure
gradient, mm Hg
0.15 0.22
85 (n  34) 1.96 1.76
85 (n  34) 2.04 1.33
Aortic valve area, cm2 0.08 0.52
0.55 (n  33) 1.87 1.57
0.55 (n  35) 2.13 1.33
Baseline aortic regurgitation
grade
NA 0.07
2 (n  48) 1.81 1.42
2 (n  20) 2.38 1.4
Intraventricular septum diameter,
mm
0.01 0.94
13 (n  35) 2.12 1.58
13 (n  33) 1.88 1.36
Baseline left ventricular ejection
fraction, %
0.05 0.69
60 (n  36) 2.15 1.51
60 (n  32) 1.83 1.42
Annulus diameter, mm 0.21 0.09
22 (n  34) 2.2 1.2
22 (n  34) 1.8 1.55
AV calciﬁcation NA 0.03
No/mild (n  23) 1.53 1.61
Moderate/severe (n  45) 2.28 1.15
Aortic sinus volume, cm3† 0.35 0.005
6.7 (n  34) 2.43 1.3
6.7 (n  34) 1.57 1.45
Aorta to aortic valve angulation,° 0.03 0.81
50 (n  34) 1.9 1.45
50 (n  34) 2.11 1.33
Procedural characteristics
Prosthesis type NA 0.49
SAPIEN (n  36) 2.12 1.32
SAPIEN XT (n  32) 1.87 1.55
Prosthetic size
23 mm (n  33) 2.13 1.21
26 mm (n  35) 1.86 1.7 NA 0.21
Vascular access NA 0.11
Transfemoral (n  43) 1.78 1.41
Transapical (n  25) 2.39 1.43
Device position during rapid
pacing‡
0.11 0.18
40% (aortic) (n  48) 1.83 1.33
40%–60% (mid position/
ventricular) (n  20)
2.37 1.63
Values aremean SD. *Devicemovement is the operator-independent change inmiddle device
position between the rapid pacing stage (immediately before balloon inflation) and deployed
valve position. †Estimation of sinus volume (cm3) was calculated as in Table 2. ‡Device position
is defined as the device fraction below the basal sinus border.appropriate cases, operators should consider placing the
m
J
c
i
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 5 , 2 0 1 2
M A Y 2 0 1 2 : 5 6 3 – 7 0
Dvir et al.
Edwards SAPIEN Positioning During TAVR
570center of the device 1 to 2 mm below the target line for
implantation during the rapid-pacing phase. The extent of
compensation should probably be greater in patients with
significant valvular calcification and/or small aortic sinus
volume. Alternatively, considering the relatively fixed posi-
tion of the upper device border, this location could be used
as a reference for its final position. Otherwise, in compli-
cated cases, prolonged and stepwise balloon inflation might
be applied with minimal correction of device position.
Study limitations. Our study was limited for not being pow-
ered to evaluate possible correlation between device location
and clinical results. The possible impact of device position on
valve function should be examined in a larger group of patients
with long-term follow-up. After device deployment, the ana-
tomic annulus plane in the base of the native aortic sinuses is
not in its original position, and any comparison of device
location to the pre-deployment location was not direct, and
some degree of bias could not be excluded. Nevertheless, we
were guided by a fixed anatomic structure created by the
sinotubular junction and the sinus curve complex. Moreover, as
detailed in the results, we found no significant difference
between pre-implantation device locations according to direct
aortographic imaging and those performed indirectly using the
calcium spot, supporting our method of analysis.
Conclusions
Our multicenter analysis of Edwards SAPIEN device positions
included only cases with reliable capture of the pacemaker and
no cases with operator-induced device movement during the
rapid-pacing stage. Our analysis shows that there is an
operator-independent upward movement of the device during
the final stage of implantation, between the final stage of rapid
pacing and deployment. This upward movement is asymmet-
rical, occurring mainly in the lower part of the device, and is
more significant in highly calcified valves and those with aortic
roots of small volume. Anticipated upward movement of the
device center should influence its positioning before final
deployment.
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